NASDAQ · STOCK
Cytokinetics
$77.06
52W $32.89 – $88.31
52/100
$9.60B
-11.3
0.42
Is CYTK Bullish or Bearish?
Mixed.
Innellis AI committee rates Cytokinetics (CYTK) Watch with a composite score of 52/100
, based on 6 analysts with 50% agreement.
Last updated July 31, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +8.48 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -11.52 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. News Analyst sees a compelling case — news sentiment is positive (+0.33 across 9 articles, 14d). Value Analyst remains cautious — price-to-book of 15.7x prices in significant intangible value. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Revenue growing 450.6% YoY -- genuine top-line momentum — Growth
- Market regime is bullish (Bull market -- normal position sizing) — Macro
- News sentiment is positive (+0.33 across 9 articles, 14d) — News
Bear Case
- Price-to-book of 15.7x prices in significant intangible value — Value
- ROE of only -131.2% -- cheap may mean cheap for a reason — Value
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- MACD histogram negative -- bearish momentum — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of July 31, 2026
Overall Committee Score
52/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 77%
of 93 Healthcare peers
Value Analyst
bearish
30
/ 100 · Moderate confidence
Multiples don't clear a genuine value bar here, or cheapness looks justified by weak fundamentals
− Price-to-book of 15.7x prices in significant intangible value
Growth Analyst
bullish
60
/ 100 · Moderate confidence
Strong, accelerating growth with consistent execution
+ Revenue growing 450.6% YoY -- genuine top-line momentum
− Growth rate is decelerating quarter over quarter -- the trend line matters more than the level
Technical Analyst
neutral
48
/ 100 · High confidence
Mixed or range-bound price action
− MACD histogram negative -- bearish momentum
Macro Analyst
neutral
58
/ 100 · Moderate confidence
Macro backdrop is mixed or neutral -- not a strong tailwind or headwind either way
+ Market regime is bullish (Bull market -- normal position sizing)
News Analyst
bullish
68
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.33 across 9 articles, 14d)
Portfolio Manager
neutral
45
/ 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2744.14)
Investment Thesis Evolution
Committee score moved marginally from 53.0 to 51.5.
- New bearish signals: 2 appeared.
- Bullish support removed: 1 signal(s) disappeared.
- New bullish signals: 2 appeared.
- Bearish pressure eased: 2 signal(s) disappeared.
- Analyst(s) changed stance: Macro Analyst.
Analyst-level changes:
- Macro Analyst: stance bullish->neutral; score 65->58 (-8); +1 bullish signal(s).
- News Analyst: +1 bullish signal(s).
- Portfolio Manager: +2 bearish signal(s).
Comparing 2026-07-30 to 2026-07-31 (1 day apart).
Technical Analysis
RSI (14)
32.6
Neutral
MACD Histogram
-0.751
Bearish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Hh Hl
Support
$66.72
Resistance
$80.01
Bollinger %B
0.04
Inside Bands
Price vs Moving Averages
EMA 9
$79.78
Below
EMA 21
$80.47
Below
EMA 50
$78.39
Below
EMA 200
$67.83
Above
Fundamental Analysis
Valuation
100
Growth
23
Profitability
1
Financial Health
100
Cash Flow
10
Valuation
P/E Ratio
-11.3×
P/B Ratio
-11.50×
PEG Ratio
0.42
Dividend Yield
0.00%
52W High
$88.31
52W Low
$32.89
Quality & Growth
ROE
119.0%
ROA
-55.1%
Gross Margin
90.3%
Operating Margin
-605.1%
Revenue Growth YoY
—
Debt / Equity
-1.56
AI Fundamental Assessment
P/E ratio of -11.3 (inexpensive relative to a 15-40x range); Price-to-book of -11.5x; PEG ratio of 0.4 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 1.2%; Return on assets of -0.6%; Net margin of -7.8%; Gross margin of 0.9%; Current ratio of 4.21 (healthy short-term liquidity); Debt-to-equity of -1.56; Free cash flow margin of 1.0% (thin cash generation); Free cash flow per share is negative (-4.45); Most recent quarter beat estimates by 0.9%; EPS growth decelerating (+41.2% -> -11.3% QoQ); Analyst estimates falling over recent quarters
Get the Full CYTK Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →